Bio-Techne (NASDAQ:TECH) Shares Acquired Rep. April McClain Delaney

Representative April McClain Delaney (D-Maryland) recently bought shares of Bio-Techne Corp (NASDAQ:TECH). In a filing disclosed on November 04th, the Representative disclosed that they had bought between $1,001 and $15,000 in Bio-Techne stock on October 22nd.

Representative April McClain Delaney also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Teledyne Technologies (NYSE:TDY) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Fortune Brands Innovations (NYSE:FBIN) on 10/31/2025.
• Purchased $1,001 – $15,000 in shares of Brown & Brown (NYSE:BRO) on 10/31/2025.
• Purchased $1,001 – $15,000 in shares of Labcorp (NYSE:LH) on 10/31/2025.
• Purchased $1,001 – $15,000 in shares of Tractor Supply (NASDAQ:TSCO) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Fortune Brands Innovations (NYSE:FBIN) on 10/29/2025.
• Purchased $1,001 – $15,000 in shares of Brown & Brown (NYSE:BRO) on 10/29/2025.
• Purchased $1,001 – $15,000 in shares of Labcorp (NYSE:LH) on 10/29/2025.
• Sold $1,001 – $15,000 in shares of Middleby (NASDAQ:MIDD) on 10/22/2025.
• Purchased $15,001 – $50,000 in shares of Nasdaq (NASDAQ:NDAQ) on 10/22/2025.

Bio-Techne Price Performance

Shares of TECH opened at $58.18 on Friday. The firm has a market cap of $9.06 billion, a PE ratio of 126.48, a price-to-earnings-growth ratio of 3.63 and a beta of 1.51. Bio-Techne Corp has a 52-week low of $46.01 and a 52-week high of $79.28. The business’s 50 day moving average price is $57.57 and its two-hundred day moving average price is $53.70. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.38 and a current ratio of 3.46.

Bio-Techne (NASDAQ:TECH) last released its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $0.42 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.42. Bio-Techne had a net margin of 6.02% and a return on equity of 13.43%. The company had revenue of $286.56 million for the quarter, compared to analysts’ expectations of $292.02 million. During the same quarter in the prior year, the firm earned $0.42 EPS. The business’s revenue was down 1.0% on a year-over-year basis. On average, equities analysts anticipate that Bio-Techne Corp will post 1.67 EPS for the current year.

Bio-Techne Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 28th. Shareholders of record on Monday, November 17th will be issued a $0.08 dividend. This represents a $0.32 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Monday, November 17th. Bio-Techne’s payout ratio is presently 69.57%.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on TECH shares. Cowen reissued a “buy” rating on shares of Bio-Techne in a research note on Tuesday, October 14th. Wells Fargo & Company increased their target price on shares of Bio-Techne from $59.00 to $70.00 and gave the company an “overweight” rating in a report on Thursday. Stephens raised Bio-Techne to a “strong-buy” rating and set a $65.00 price objective on the stock in a research report on Tuesday, July 22nd. TD Cowen raised their price target on shares of Bio-Techne from $65.00 to $70.00 and gave the stock a “buy” rating in a research note on Tuesday, October 14th. Finally, Royal Bank Of Canada upgraded shares of Bio-Techne from a “hold” rating to a “moderate buy” rating in a research report on Wednesday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $71.17.

Institutional Investors Weigh In On Bio-Techne

A number of institutional investors have recently made changes to their positions in the business. Select Equity Group L.P. increased its position in shares of Bio-Techne by 129.8% during the first quarter. Select Equity Group L.P. now owns 5,366,003 shares of the biotechnology company’s stock valued at $314,609,000 after buying an additional 3,030,644 shares during the period. Norges Bank purchased a new stake in shares of Bio-Techne during the second quarter valued at approximately $98,238,000. RGM Capital LLC bought a new stake in shares of Bio-Techne in the 1st quarter worth $59,267,000. Madison Asset Management LLC bought a new stake in Bio-Techne in the 3rd quarter worth about $41,425,000. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Bio-Techne by 6.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 11,375,279 shares of the biotechnology company’s stock valued at $666,933,000 after purchasing an additional 721,012 shares during the last quarter. Hedge funds and other institutional investors own 98.95% of the company’s stock.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.